Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer

Summary

This study investigates the potential of seminal fluid as a non-invasive liquid biopsy for detecting clinically significant prostate cancer. Seminal fluid samples were collected at home from 279 men scheduled for prostate biopsy, and their cell-free DNA (cfDNA) underwent methylation analysis. Researchers characterized seminal cfDNA, identifying granulocytes and sperm as primary contributors, but confirming the detectable presence of prostate-derived cfDNA. Fragment-level methylation features were analyzed to identify signals associated with clinically significant prostate cancer, highlighting the promise of this approach for diagnosis and monitoring.

Critical appraisal

This exploratory study, conducted on 279 men across 12 sites, demonstrates the potential of seminal fluid as a non-invasive source for detecting clinically significant prostate cancer. Home collection simplifies acquisition, potentially improving patient compliance and screening feasibility. If validated in larger prospective studies, this method could serve as a diagnostic or monitoring biomarker, potentially reducing the need for invasive biopsies. Clinical impact could materialize in 3 to 5 years, justifying clinical trials to evaluate its diagnostic performance against current methods.

The research characterized cfDNA in seminal fluid, confirming the abundance of high molecular weight cfDNA and the detectable presence of prostate-derived cfDNA. cfDNA methylation analysis was employed to identify prostate cancer-specific features, likely via next-generation sequencing platforms. The challenge of tissue-of-origin deconvolution (granulocytes, sperm) was addressed by using fragment-level methylation features, crucial for analytical validity. Seminal fluid, as a non-invasive liquid biopsy, offers advantages over tissue biopsies for diagnosis.

The study utilized bioinformatics methods for cfDNA tissue-of-origin deconvolution and the identification of cancer-specific methylation signatures. A key approach involved using fragment-level DNA methylation features to characterize and quantify the prostate cancer-related signal, overcoming confounding from different tissue origins. Unsupervised clustering was also applied to identify distinct populations. This bioinformatics approach is essential for extracting relevant information from a complex sample and could eventually be integrated into a clinical diagnostic pipeline for automated methylation data analysis.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology